Data / Public companies / Biological products, (no diagnostic substances)

Biological products, (no diagnostic substances) (SIC 2836): 172 companies that file annual reports with the SEC

Name: Biological products, (no diagnostic substances) companies that file annual reports with the SEC
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

Updated September 30, 2026. Source: SEC Financial Statement Data Sets (sec.gov).

172 companies that file annual reports with the SEC have the industry code SIC 2836 (Biological products, (no diagnostic substances)), in the data filed through September 30, 2026. 89 report revenue, a combined $96.32 billion, with a median of $39.6 million. 14.6% of the 157 that report net income show a profit. The largest by revenue is Amgen Inc ($36.75 billion).

The request: Get every company that files with the SEC in the industry Biological products, (no diagnostic substances) (SIC 2836), with its revenue, website and number of employees. $10 of work on sign-up, no card.

Companies in biological products, (no diagnostic substances)Watch new annual reports Check my company list

SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.

SIC code: 2836
SEC industry title: Biological Products, (No Diagnostic Substances)
Division: Manufacturing
Companies with an annual report in the data: 172
Companies that report revenue: 89
Combined revenue: $96.32 billion
Median revenue: $39.6 million
Reported a net profit: 23 of 157 (14.6%)
Combined total assets: $259.05 billion
Large accelerated filers: 38
Newest annual report filed: September 10, 2026

Largest by revenue

Latest fiscal year, from each company's annual report. Each name links to the company's page.

Company	Business address	Revenue	Net income	Total assets	Revenue change
Amgen Inc	Thousand Oaks, CA	$36.75 billion	$7.71 billion	$90.59 billion	10%
Gilead Sciences, Inc.	Foster City, CA	$29.44 billion	$8.51 billion	$59.02 billion	2.4%
Biogen Inc.	Cambridge, MA	$9.89 billion	$1.29 billion	$29.44 billion	2.2%
Neurocrine Biosciences Inc	San Diego, CA	$2.86 billion	$478.6 million	$4.63 billion	21.4%
Exelixis, Inc.	Alameda, CA	$2.32 billion	$782.6 million	$2.84 billion	7%
Qiagen N.V.	PL Venlo	$2.09 billion	$424.9 million	$6.28 billion	5.7%
Moderna, Inc.	Cambridge, MA	$1.94 billion	$-2,822,000,000	$12.34 billion	-39.9%
Halozyme Therapeutics, Inc.	San Diego, CA	$1.40 billion	$316.9 million	$2.53 billion	37.6%
Bio-Techne Corp	Minneapolis, MN	$1.22 billion	$181.9 million	$2.59 billion	-0.4%
Novavax Inc	Gaithersburg, MD	$1.12 billion	$440.3 million	$1.18 billion	64.7%
Biocryst Pharmaceuticals Inc	Durham, NC	$874.8 million	$263.9 million	$514.2 million	94.1%
Repligen Corp	Waltham, MA	$738.3 million	$48.9 million	$2.95 billion	16.4%
Adma Biologics, Inc.	Ramsey, NJ	$510.2 million	$146.9 million	$624.2 million	19.6%
Tarsus Pharmaceuticals, Inc.	Irvine, CA	$451.4 million	$-66,418,000	$562.2 million	146.7%
Immunocore Holdings PLC	Oxfordshire, United Kingdom	$400 million	$-35,514,000	$1.07 billion	29%
Krystal Biotech, Inc.	Pittsburgh, PA	$389.1 million	$204.8 million	$1.33 billion	33.9%
Twist Bioscience Corp	South San Francisco, CA	$376.6 million	$-77,670,000	$641.9 million	20.3%
Adaptive Biotechnologies Corp	Seattle, WA	$277 million	$-59,499,000	$512.7 million	54.8%
Vericel Corp	Cambridge, MA	$276.3 million	$16.5 million	$488 million	16.5%
Iovance Biotherapeutics, Inc.	San Carlos, CA	$263.5 million	$-390,978,000	$913.2 million	60.6%
Vaxart, Inc.	South San Francisco, CA	$237.3 million	$16.3 million	$186.1 million	726.7%
Regenxbio Inc.	Rockville, MD	$170.4 million	$-193,878,000	$453 million	104.5%
Ginkgo Bioworks Holdings, Inc.	Boston, MA	$170.2 million	$-312,763,000	$1.12 billion	-25.1%
Beam Therapeutics Inc.	Cambridge, MA	$139.7 million	$-79,992,000	$1.48 billion	120%
Monte Rosa Therapeutics, Inc.	Boston, MA	$123.7 million	$-38,626,000	$448.7 million	63.5%

Largest by total assets

Company	Business address	Revenue	Net income	Total assets
Amgen Inc	Thousand Oaks, CA	$36.75 billion	$7.71 billion	$90.59 billion
Gilead Sciences, Inc.	Foster City, CA	$29.44 billion	$8.51 billion	$59.02 billion
Biogen Inc.	Cambridge, MA	$9.89 billion	$1.29 billion	$29.44 billion
Moderna, Inc.	Cambridge, MA	$1.94 billion	$-2,822,000,000	$12.34 billion
Qiagen N.V.	PL Venlo	$2.09 billion	$424.9 million	$6.28 billion
Neurocrine Biosciences Inc	San Diego, CA	$2.86 billion	$478.6 million	$4.63 billion
Vaxcyte, Inc.	San Carlos, CA	Not listed	$-766,628,000	$3.00 billion
Repligen Corp	Waltham, MA	$738.3 million	$48.9 million	$2.95 billion
Exelixis, Inc.	Alameda, CA	$2.32 billion	$782.6 million	$2.84 billion
Bio-Techne Corp	Minneapolis, MN	$1.22 billion	$181.9 million	$2.59 billion
Halozyme Therapeutics, Inc.	San Diego, CA	$1.40 billion	$316.9 million	$2.53 billion
Revolution Medicines, Inc.	Redwood City, CA	$0	$-1,131,301,000	$2.35 billion
Crispr Therapeutics AG	Zug	$3.5 million	$-581,599,000	$2.27 billion
Kymera Therapeutics, Inc.	Watertown, MA	$39.2 million	$-311,351,000	$1.74 billion
Beam Therapeutics Inc.	Cambridge, MA	$139.7 million	$-79,992,000	$1.48 billion

Companies by size of revenue

Companies that report revenue, by the revenue in their latest annual report.

Revenue	Companies	Share
Under $10 million	28	31.5%
$10 million to $100 million	31	34.8%
$100 million to $1 billion	20	22.5%
$1 billion to $10 billion	8	9%
$10 billion and over	2	2.2%

States with the most companies

By state of the business address.

State	Companies	Share	Combined revenue
California	58	33.7%	$74.83 billion
Massachusetts	31	18%	$13.70 billion
New York	9	5.2%	$81.4 million
North Carolina	8	4.7%	$973.5 million
Florida	6	3.5%	$8.4 million
New Jersey	6	3.5%	$564.3 million
Pennsylvania	5	2.9%	$502.7 million
Maryland	4	2.3%	$1.37 billion
Texas	4	2.3%	$20 million
Washington	3	1.7%	$277 million
Connecticut	2	1.2%	$53.4 million
Delaware	2	1.2%	$0
Arizona	1	0.6%	$6,000
Colorado	1	0.6%	$2.1 million
Minnesota	1	0.6%	$1.22 billion

Newest annual reports

By the date the company filed its latest annual report with the SEC.

Company	Filed	Fiscal year ended	Form	Revenue
Pluri Inc.	September 10, 2026	June 30, 2026	10-K	$1 million
Mesoblast LTD	August 27, 2026	June 30, 2026	20-F	Not listed
Bio-Techne Corp	August 24, 2026	June 30, 2026	10-K	$1.22 billion
Pharmacyte Biotech, Inc.	July 29, 2026	April 30, 2026	10-K	$0
Champions Oncology, Inc.	July 27, 2026	April 30, 2026	10-K	$59.4 million
Okyo Pharma LTD	July 20, 2026	March 31, 2026	20-F	Not listed
Vivosim Labs, Inc.	July 14, 2026	March 31, 2026	10-K	$131,000
Agentix Corp.	July 1, 2026	March 31, 2026	10-K	Not listed
Replimune Group, Inc.	June 29, 2026	March 31, 2026	10-K	Not listed
Immunovant, Inc.	May 20, 2026	March 31, 2026	10-K	Not listed
Agomab Therapeutics NV	April 23, 2026	December 31, 2025	20-F	Not listed
Mosaic Immunoengineering Inc.	April 15, 2026	December 31, 2025	10-K	Not listed

Filer category

The SEC's size class for the company when it filed.

Category	Companies	Share
Non-accelerated filer	122	70.9%
Large accelerated filer	38	22.1%
Accelerated filer	11	6.4%

Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.